GRP78 confers the resistance to 5-FU by activating the c-Src/LSF/TS Axis in hepatocellular carcinoma

5-FU is a common first-line chemotherapeutic drug for the treatment of hepatocellular carcinoma. However the development of acquired resistance to 5-FU confines its clinical usages. Although this phenomenon has been the subject of intense investigation, the exact mechanism of acquired resistance to...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Gu, Yan-jiao, Li, Hong-dan, Zhao, Liang, Zhao, Song, He, Wu-bin, Rui, Li, Su, Chang, Zheng, Hua-chuan, Su, Rong-jian
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4741793/
https://ncbi.nlm.nih.gov/pubmed/26378040
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares